Literature DB >> 10628557

Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution.

M R Zalutsky1, F J Xu, Y Yu, C F Foulon, X G Zhao, S K Slade, D J Affleck, R C Bast.   

Abstract

Monoclonal antibody (MAb) internalization can have a major effect on tumor retention of radiolabel. Two anti-HER-2/neu MAbs (TA1 and 520C9) were radioiodinated using the iodogen, N-succinimidyl 5-iodo-3-pyridinecarboxylate (SIPC), and tyramine-cellobiose (TCB) methods. Paired-label studies compared internalization and cellular processing of the labeled MAbs by SKOv3 9002-18 ovarian cancer cells in vitro. Intracellular radioiodine activity for 520C9 was up to 2.6 and 3.0 times higher for SIPC and TCB labeling, respectively, compared with iodogen. Likewise, intracellular activity for TA1 was up to 2.3 and 2.9 times higher with the SIPC and TCB methods compared with iodogen labeling. Unfortunately, similar advantages in tumor accumulation were not achieved in athymic mice bearing SKOv3 9008-18 ovarian cancer xenografts.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10628557     DOI: 10.1016/s0969-8051(99)00060-8

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  4 in total

Review 1.  Preclinical development of molecular-targeted agents for cancer.

Authors:  Alberto Ocana; Atanasio Pandiella; Lillian L Siu; Ian F Tannock
Journal:  Nat Rev Clin Oncol       Date:  2010-12-07       Impact factor: 66.675

2.  Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence.

Authors:  Torun Engfeldt; Anna Orlova; Thuy Tran; Alexander Bruskin; Charles Widström; Amelie Eriksson Karlström; Vladimir Tolmachev
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-12-05       Impact factor: 9.236

Review 3.  Understanding the in vivo fate of radioimmunoconjugates for nuclear imaging.

Authors:  Delphine Vivier; Sai Kiran Sharma; Brian M Zeglis
Journal:  J Labelled Comp Radiopharm       Date:  2018-05-14       Impact factor: 1.921

4.  Preclinical characterisation of 111In-DTPA-trastuzumab.

Authors:  Marjolijn N Lub-de Hooge; Jos G W Kosterink; Patrick J Perik; Hugo Nijnuis; Ly Tran; Joost Bart; Albert J H Suurmeijer; Steven de Jong; Pieter L Jager; Elisabeth G E de Vries
Journal:  Br J Pharmacol       Date:  2004-08-02       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.